1435.1 - Processing and Cryopreservation of Ovarian Tissue

Page last updated: 01 April 2020

Application Detail



Description of Medical Service

The proposed medical service is for processing and cryopreservation (freezing) of ovarian tissue (partial or whole ovary removal), for fertility preservation both prior to receiving or following completion of gonadotoxic treatment for malignant or non-malignant conditions in patients aged 0-40 years, and for thawing and preparation of ovarian tissue prior to ovarian tissue transplant (OTT) in patients wanting to have a biological pregnancy if they are infertile.

Description of Medical Condition

The proposed patient population is defined by the requirement of gonadotoxic therapy. Specifically, the proposed population is females aged 0 to 40 years (pre pubertal and post pubertal) who are scheduled to undergo, or have completed gonadotoxic treatment. Gonadotoxic treatment includes any treatment which is associated with an intermediate or high risk of ovarian damage or sterility. This can include treatment such as chemotherapy, conditioning therapy for bone-marrow transplantation, pelvic surgery, or pelvic irradiation. Cancer is the primary group of diseases for which women are likely to undergo gonadotoxic treatment and would account for an estimated 78% of cases eligible for OTC.

Reason for Application


Medical Service Type


Previous Application Number


Associated Documentation

Application Form


Consultation Survey

Feedback and comments are welcome at any stage during the MSAC process. Please provide comments on Application 1435.1 via a maximum of two A4 pages to HTA@health.gov.au (making sure that you type the application number at the start of your comments and in the subject heading of your email).

PICO Confirmation


Assessment Report


Public Summary Document

Public Summary Document (PDF 791 KB)
Public Summary Document (Word 460 KB)

Meetings for this Application


11 - 12 August 2016


13 June 2019


1-2 August 2019